Evotec SE (Evotec) provides drug discovery and development solutions. The company works in partnership with pharmaceutical companies, small and large biotechnology companies, patient advocacy groups and academic institutions for the discovery and development of pharmaceutical products. It specializes in various disease areas, including oncology, central nervous system disorders, metabolic diseases, cardio-metabolic disorders, autoimmune, inflammatory, infectious diseases, fibrotic and respiratory diseases, rare diseases, and animal health. The company operates in two business segments, namely, Shared R&D and Just – Evotec Biologics. Its major services include integrated drug discovery services, target ID and validation services, compound management services, drug metabolism and pharmacokinetics, research informatics and in-silico drug discovery services, proteomics and metabolomics screening, cell and protein production, and in vitro and in vivo pharmacology services.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Evotec focused its research and development activities in 2025 on platforms covering strategic opportunities, therapeutic area investments, and segment innovation to strengthen underlying platforms. The strategic opportunities include investments in platforms such as E.MPD, PanOmics, PanHunter, iPSC drug development, iPSC cell therapy, and targeted protein degradation. These efforts support the development of a long-term pipeline of assets and/or unique proprietary platforms. This unit is responsible for drug discovery and preclinical development services and solutions, starting with sourcing novel treatment ideas derived from patient data and continuing with target validation and lead optimization. The unit emphasizes operational excellence towards higher-margin activities, complexity reduction, operational streamlining, and an "asset-lighter" operational model. As of December 31, 2025, Evotec SE operated 14 sites. The company has filed patent applications in the US, Europe, and abroad related to its pipeline assets, processes, or other technologies. As of December 2025, the portfolio of projects in clinical trials included two projects in Phase II and five projects in Phase I. There were 62 active partnered projects, excluding 21 projects with royalties only, and an additional 31 projects eligible for partnering in the future. Major technology alliances include collaborations with leading pharmaceutical companies, small and large biotechnology companies, academic institutions, patient advocacy groups, venture capitalists, mission-driven foundations, and not-for-profit organizations. In FY2025, the company spent EUR35.7 million on its R&D activities, which as a percentage of revenue stood at 4.5%.